Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Neutocid-LS
- Development stage
- Unknown
- Lead developer
- Dios Lifesciences
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Neutocid-LS is a marketed fixed-dose combination therapy developed by Dios Lifesciences for the treatment of gastrointestinal disorders, including gastroesophageal reflux disease (GERD), intestinal ulcers, and irritable bowel syndrome (IBS). It contains rabeprazole, a proton pump inhibitor that reduces gastric acid secretion by inhibiting the H+/K+ ATPase enzyme in the stomach wall, and levosulpiride, a prokinetic agent that acts as a selective dopamine D2 receptor antagonist to enhance gastrointestinal motility and accelerate gastric emptying. This combination addresses both acid-related symptoms and motility issues like bloating and flatulence. It is typically formulated as a sustained-release capsule to provide prolonged therapeutic effects.
- Brand names
- Neutocid-LS
- Other names
- levosulpiride + rabeprazole
02
Targets
DRD2 (Dopamine D2 Receptor)ATP4A (Potassium–transporting ATPase alpha chain 1)
Beyond the preview
Go deeper on Neutocid-LS.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Neutocid-LS.